Login / Signup
Claus Sværke
ORCID
Publication Activity (10 Years)
Years Active: 2024-2024
Publications (10 Years): 5
Top Topics
Double Blind
Placebo Controlled
Phase Iii
Growth Hormone
Top Venues
Clinical pharmacokinetics
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Sarah Louise Dombernowsky
,
Birgitte Bentz Damholt
,
Michael Højby Rasmussen
,
Claus Sværke
,
Rasmus Juul Kildemoes
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial.
Clinical pharmacokinetics
63 (7) (2024)
Sarah Louise Dombernowsky
,
Birgitte Bentz Damholt
,
Michael Højby Rasmussen
,
Claus Sværke
,
Rasmus Juul Kildemoes
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial.
Clinical pharmacokinetics
(2024)
Sarah Louise Dombernowsky
,
Birgitte Bentz Damholt
,
Michael Højby Rasmussen
,
Claus Sværke
,
Rasmus Juul Kildemoes
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial.
Clinical pharmacokinetics
63 (7) (2024)
Sarah Louise Dombernowsky
,
Birgitte Bentz Damholt
,
Michael Højby Rasmussen
,
Claus Sværke
,
Rasmus Juul Kildemoes
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial.
Clinical pharmacokinetics
63 (7) (2024)
Sarah Louise Dombernowsky
,
Birgitte Bentz Damholt
,
Michael Højby Rasmussen
,
Claus Sværke
,
Rasmus Juul Kildemoes
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial.
Clinical pharmacokinetics
63 (7) (2024)